Core Insights - The company reported a revenue of 436 million yuan for the first half of the year, representing a year-on-year growth of 27.94%, and a net profit attributable to shareholders of 31 million yuan, reflecting a significant increase of 257.08% [1] Group 1: Business Overview - The company has established itself as a global leader in the fine chemicals manufacturing sector, particularly excelling in fluorinated fine chemicals [2] - It has developed a global integrated research, production, and sales network with three main production bases in Shanghai, Zhejiang, and Lanzhou, alongside an international base in the USA [2] - The Lanzhou base is crucial for regional expansion and product diversification, enhancing the company's control over the supply chain in fluorinated chemicals and organic silicon [2] Group 2: Technological Advancements - Continuous R&D investment and key technological breakthroughs are the company's core competitive advantages, leading to the development of high-tech, high-value-added products [3] - The company is one of the first globally to achieve mass production of a new electrolyte for lithium batteries, significantly advancing the domestic production of high-quality lithium battery materials [3] - It has also developed a series of high-performance lithium battery electrolyte additives, achieving an average annual compound growth rate of over 40% in recent years [3] Group 3: Capacity Adjustment and Future Plans - The company plans to leverage its R&D support and brand influence to expand capacity and market reach, particularly through the Lanzhou base, which is projected to generate an annual sales revenue of 1 billion yuan upon full operation [4] - The company is adjusting its investment focus towards new materials and peptide pharmaceuticals, with specific projects aimed at enhancing production capabilities in these areas [5] - New projects include a 25,500-ton annual capacity battery materials project in Lanzhou, which has been adjusted to a 5,000-ton capacity for the first phase, and additional projects in Zhuzhou and Shanghai targeting new materials and peptide production [5]